{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:06:42Z","timestamp":1793869602878,"version":"4.6.1"},"reference-count":96,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006506","name":"Minist\u00e9rio da Sa\u00fade","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006506","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Carlos Chagas Filho Foundation for Research Support of Rio de Janeiro State","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.omton.2025.200980","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T22:24:08Z","timestamp":1743805448000},"page":"200980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Cost-effective strategies for CAR-T cell therapy manufacturing"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4381-9123","authenticated-orcid":false,"given":"Luiza","family":"Abdo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Ribeiro","family":"Batista-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn Hern\u00e1n","family":"Bonamino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.200980_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200980_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1615\/CritRevImmunol.2021037551","article-title":"Structural Determinants of Chimeric Antigen Receptor Design","volume":"41","author":"Abdo","year":"2021","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.omton.2025.200980_bib3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/biom11020238","article-title":"The Application of Nanobody in CAR-T Therapy","volume":"11","author":"Bao","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.omton.2025.200980_bib4","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.200980_bib5","volume":"27","author":"Rebecca Borgert","year":"2021"},{"key":"10.1016\/j.omton.2025.200980_bib6","series-title":"Chimeric Antigen Receptor T Cells: Development and Production Methods in Molecular Biology","first-page":"131","article-title":"Generation of CAR+ T Lymphocytes Using the Sleeping Beauty Transposon System","author":"Chicaybam","year":"2020"},{"key":"10.1016\/j.omton.2025.200980_bib7","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3109\/14653240903219114","article-title":"Impact of culture medium on the expansion of T cells for immunotherapy","volume":"11","author":"Sato","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2025.200980_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1089\/hgtb.2016.120","article-title":"A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies","volume":"27","author":"Lu","year":"2016","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omton.2025.200980_bib9","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2025.200980_bib10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.200980_bib11","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.200980_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/d41586-024-00809-y","article-title":"Cutting-edge CAR-T cancer therapy is now made in India \u2014 at one-tenth the cost","volume":"627","author":"Mallapaty","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.200980_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/bs.mcb.2021.07.001","article-title":"Generation of CAR-T cells using lentiviral vectors","volume":"167","author":"Poorebrahim","year":"2022","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.omton.2025.200980_bib14","series-title":"Chimeric Antigen Receptor T Cells: Development and Production Methods in Molecular Biology","first-page":"69","article-title":"Optimized Production of Lentiviral Vectors for CAR-T Cell","author":"Mo\u00e7o","year":"2020"},{"key":"10.1016\/j.omton.2025.200980_bib15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/bs.mcb.2021.06.014","article-title":"Generation of CAR T-cells using \u03b3-retroviral vector","volume":"167","author":"Watanabe","year":"2022","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.omton.2025.200980_bib16","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS)","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200980_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03478-6","article-title":"Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies","author":"Jadlowsky","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.200980_bib18","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2025.200980_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cryobiol.2018.06.007","article-title":"Effects of cryopreservation on chimeric antigen receptor T cell functions","volume":"83","author":"Xu","year":"2018","journal-title":"Cryobiology"},{"key":"10.1016\/j.omton.2025.200980_bib20","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.3390\/ijms22105084","article-title":"Contemporary Transposon Tools: A Review and Guide through Mechanisms and Applications of Sleeping Beauty, piggyBac and Tol2 for Genome Engineering","volume":"22","author":"Sandoval-Villegas","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2025.200980_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12967-016-1047-x","article-title":"Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives","volume":"14","author":"Vargas","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omton.2025.200980_bib22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0092-8674(00)80436-5","article-title":"Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells","volume":"91","author":"Ivics","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.omton.2025.200980_bib23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0042-6822(89)90117-7","article-title":"Transposon mutagenesis of baculoviruses: analysis of Trichoplusia ni transposon IFP2 insertions within the FP-locus of nuclear polyhedrosis viruses","volume":"172","author":"Cary","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.omton.2025.200980_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005189","article-title":"Automated, scaled, transposon-based production of CAR T cells","volume":"10","author":"Lock","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.200980_bib25","article-title":"Non-viral chimeric antigen receptor (CAR) T cells going viral","volume":"18","author":"Balke-Want","year":"2023","journal-title":"Immunooncol. Technol."},{"key":"10.1016\/j.omton.2025.200980_bib26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0022-2836(02)00991-9","article-title":"Common physical properties of DNA affecting target site selection of sleeping beauty and other Tc1\/mariner transposable elements","volume":"323","author":"Vigdal","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.omton.2025.200980_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1006\/viro.1995.1422","article-title":"Assay for movement of Lepidopteran transposon IFP2 in insect cells using a baculovirus genome as a target DNA","volume":"211","author":"Fraser","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.omton.2025.200980_bib28","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2025.200980_bib29","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood.2019002920","article-title":"Long-term outcomes of Sleeping Beauty\u2013generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas","volume":"135","author":"Srour","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200980_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032397","article-title":"Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies","volume":"13","author":"Singh","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.200980_bib31","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1172\/JCI138473","article-title":"Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2025.200980_bib32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2025.200980_bib33","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200980_bib34","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.ymthe.2018.05.007","article-title":"PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts","volume":"26","author":"Bishop","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.200980_bib35","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200980_bib36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR-Cas9 Structures and Mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.omton.2025.200980_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.200980_bib38","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1089\/hum.2024.020","article-title":"Cell-Penetrating Peptides and CRISPR-Cas9: A Combined Strategy for Human Genetic Disease Therapy","volume":"35","author":"de Morais","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2025.200980_bib39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1365-201X.2003.01093.x","article-title":"Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research","volume":"177","author":"Gehl","year":"2003","journal-title":"Acta Physiol. Scand."},{"key":"10.1016\/j.omton.2025.200980_bib40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.200980_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf1333","article-title":"A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells","volume":"7","author":"Bozza","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omton.2025.200980_bib42","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.2147\/IJN.S424723","article-title":"Delivery of Plasmid DNA by Ionizable Lipid Nanoparticles to Induce CAR Expression in T Cells","volume":"18","author":"Prazeres","year":"2023","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.omton.2025.200980_bib43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","article-title":"Chimeric antigen receptor therapy meets mRNA technology","volume":"42","author":"Wu","year":"2024","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.omton.2025.200980_bib44","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omton.2025.200980_bib45","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.200980_bib46","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omton.2025.200980_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1752592","article-title":"Development of CAR-T cell therapy for B-ALL using a point-of-care approach","volume":"9","author":"de Macedo Abdo","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2025.200980_bib48","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1182\/blood-2023-188214","article-title":"Development and Clinical Validation of an Ultra-Fast CAR-T Manufacturing Platform Enabling Production of CAR-T Cells in Less Than 1 Day","volume":"142","author":"Stadel","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200980_bib49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","article-title":"Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study","volume":"12","author":"Yang","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2025.200980_bib50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.omton.2025.200980_bib51","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omton.2025.200980_bib52","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2025.200980_bib53","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3389\/fimmu.2020.01941","article-title":"Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma","volume":"11","author":"Jackson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.200980_bib54","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/eji.201343751","article-title":"The who\u2019s who of T-cell differentiation: Human memory T-cell subsets","volume":"43","author":"Mahnke","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omton.2025.200980_bib55","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.200980_bib56","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2025.200980_bib57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41434-020-0121-4","article-title":"Transposon-mediated generation of CAR-T cells shows efficient anti B-cell leukemia response after ex vivo expansion","volume":"27","author":"Chicaybam","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2025.200980_bib58","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200980_bib59","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-Engineered Universal CD19\/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed\/Refractory B-cell Acute Lymphoblastic Leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.200980_bib60","doi-asserted-by":"crossref","first-page":"eabq3010","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2025.200980_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.bmt.1702477","article-title":"CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells","volume":"26","author":"Hale","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2025.200980_bib62","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.200980_bib63","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","article-title":"Long Terminal Repeat CRISPR-CAR-Coupled \u201cUniversal\u201d T Cells Mediate Potent Anti-leukemic Effects","volume":"26","author":"Georgiadis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.200980_bib64","article-title":"Allogene Therapeutics Launches CAR T Together\u2122, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for \u201cOff-The-Shelf\u201d Allogeneic Cell Therapy Investigational Products","year":"2022","journal-title":"Allogene Therapeut."},{"key":"10.1016\/j.omton.2025.200980_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115123","article-title":"IPSC-derived CAR-NK cells for cancer immunotherapy","volume":"165","author":"Lin","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omton.2025.200980_bib66","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.3390\/cancers14092266","article-title":"Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy","volume":"14","author":"Zhou","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.200980_bib67","unstructured":"Pipeline Fate Therapeutics. https:\/\/fatetherapeutics.com\/pipeline\/."},{"key":"10.1016\/j.omton.2025.200980_bib68","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jcyt.2020.08.007","article-title":"Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation","volume":"23","author":"Lam","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2025.200980_bib69","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2025.200980_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front. Transplant."},{"key":"10.1016\/j.omton.2025.200980_bib71","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jtct.2022.02.017","article-title":"Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma","volume":"28","author":"Kedmi","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2025.200980_bib72","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jcyt.2021.04.003","article-title":"Advances in automated cell washing and concentration","volume":"23","author":"Li","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2025.200980_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of Manufacturing Procedures on CAR T Cell Functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.200980_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.200980_bib75","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11626-018-0273-3","article-title":"Influence of various medium environment to in vitro human T cell culture","volume":"54","author":"Xu","year":"2018","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"10.1016\/j.omton.2025.200980_bib76","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.omtm.2017.11.001","article-title":"Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium","volume":"8","author":"Medvec","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2025.200980_bib77","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jcyt.2018.04.007","article-title":"Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells","volume":"20","author":"Alnabhan","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2025.200980_bib78","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200980_bib79","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200980_bib80","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.omton.2025.200980_bib81","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1182\/blood-2007-09-113050","article-title":"IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy","volume":"111","author":"Hinrichs","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200980_bib82","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1158\/2159-8290.CD-20-0896","article-title":"A Chimeric GM-CSF\/IL18 Receptor to Sustain CAR T-cell Function","volume":"11","author":"Lange","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2025.200980_bib83","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2025.200980_bib84","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1096\/fj.201901809R","article-title":"IL-18R-dependent and independent pathways account for IL-18-enhanced antitumor ability of CAR-T cells","volume":"34","author":"Huang","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.omton.2025.200980_bib85","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2025.200980_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101459","article-title":"Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies","volume":"22","author":"Atilla","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.omton.2025.200980_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2025.200980_bib88","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.200980_bib89","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.200980_bib90","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/bloodadvances.2024012563","article-title":"Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in lymphoma patients","volume":"8","author":"Carniti","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2025.200980_bib91","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2025.200980_bib92","first-page":"578","article-title":"Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)","volume":"130","author":"Neelapu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200980_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116203","article-title":"Tumor immunotherapy resistance: Revealing the mechanism of PD-1\/PD-L1-mediated tumor immune escape","volume":"171","author":"Cui","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omton.2025.200980_bib94","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1182\/bloodadvances.2022008977","article-title":"A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia","volume":"7","author":"Masih","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2025.200980_bib95","article-title":"Targeting PRC2 enhances the cytotoxic capacity of anti-CD19 CAR-T cells against hematological malignancies","author":"Carvalho","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.200980_bib96","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ymthe.2022.04.002","article-title":"Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India","volume":"30","author":"Cornetta","year":"2022","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:03:51Z","timestamp":1762657431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925000499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2950329925000499"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.200980","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effective strategies for CAR-T cell therapy manufacturing","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.200980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"200980"}}